Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Cantor Fitzgerald

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by research analysts at Cantor Fitzgerald to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

IKT has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Wednesday, October 8th. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of Inhibikase Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Finally, Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Inhibikase Therapeutics Stock Up 1.0%

NASDAQ:IKT opened at $1.54 on Thursday. The stock has a 50-day moving average price of $1.55. Inhibikase Therapeutics has a 12 month low of $1.33 and a 12 month high of $4.20. The stock has a market capitalization of $115.78 million, a P/E ratio of -3.95 and a beta of 0.88.

Inhibikase Therapeutics (NASDAQ:IKT) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.